» Articles » PMID: 38469361

Safety of Ashitaba Sap As a Novel Food Pursuant to Regulation (EU) 2015/2283

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on ashitaba sap as a novel food (NF) pursuant to Regulation (EU) 2015/2283. Ashitaba sap is collected from harvested stems of plants. The principal constituents of the sap with regard to the safety assessment are chalcones (1%-2.25%) and furanocoumarins (< 0.01%). The applicant proposed to use the NF in food supplements at a maximum dose of 780 mg per day. The target population is adults excluding pregnant and lactating women. Taking into consideration the composition of the NF and the proposed uses, the composition of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90-day oral toxicity study performed with the product as intended to be placed on the market (30% ashitaba sap powder and 70% cyclodextrins), the Panel establishes a safe dose of 0.5 mg/kg body weight (bw) per day for the product as it is intended to be placed on the market. For the target population, i.e. adults, this safe dose corresponds to 35 mg per day of the product as it is intended to be placed on the market and 137 mg per day of the NF, which is lower than the use level proposed by the applicant. The Panel concludes that the NF is safe for the target population at intake levels up to 137 mg per day.

Citing Articles

Nephroprotective Activity of (Miq). Koidz. on Cisplatin-Induced Rats: Reducing Serum Creatinine, Urea Nitrogen, KIM-1, and Suppressing NF-kappaB p65 and COX-2.

Wahyuni I, Aulifa D, Rosdianto A, Levita J Drug Des Devel Ther. 2024; 18:4707-4721.

PMID: 39469724 PMC: 11514653. DOI: 10.2147/DDDT.S481479.


Safety of ashitaba sap as a Novel food pursuant to Regulation (EU) 2015/2283.

Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst K, Maciuk A EFSA J. 2024; 22(3):e8645.

PMID: 38469361 PMC: 10926279. DOI: 10.2903/j.efsa.2024.8645.

References
1.
Nagata J, Morino T, Saito M . Effects of dietary Angelica keiskei on serum and liver lipid profiles, and body fat accumulations in rats. J Nutr Sci Vitaminol (Tokyo). 2007; 53(2):133-7. DOI: 10.3177/jnsv.53.133. View

2.
Ogawa H, Nakashima S, Baba K . Effects of dietary Angelica keiskei on lipid metabolism in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2003; 30(4):284-8. DOI: 10.1046/j.1440-1681.2003.03830.x. View

3.
Lo H, Huang T, Lin C, Peng H, Wu W . 2'-Ethoxy-5'-methoxy-2-(5-methylthienyl)chalcone inhibits collagen-induced protein tyrosine phosphorylation and thromboxane formation during platelet aggregation and adhesion. Pharmacology. 2009; 84(3):145-52. DOI: 10.1159/000235584. View

4.
Ko H, Hsieh H, Liu C, Lin H, Teng C, Lin C . Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation. J Pharm Pharmacol. 2004; 56(10):1333-7. DOI: 10.1211/0022357044247. View

5.
Utsunomiya N, Oyama N, Chino T, Utsunomiya A, Hida Y, Hasegawa M . Dietary supplement product composed of natural ingredients as a suspected cause of erythema multiforme: A case report and identification for the confident false positivity of lymphocyte transformation test. J Dermatol. 2019; 46(3):234-239. DOI: 10.1111/1346-8138.14739. View